Should you get the COVID-19 vaccine if you lack the cells that make antibodies?
Multiple sclerosis (MS) is an autoimmune disorder that is often treated with drugs that deplete B cells and therefore interfere in the process of antibody production.
Added benefit: A single dose of COVID-19 vaccine can also protect your loved ones at home
Researchers from Public Health England followed COVID-19 vaccine recipients nationwide to measure their risk of infection and transmission.
Promising news for pregnant women: take one shot and help two!
Findings in recent issues of JAMA Pediatrics and The New England Journal of Medicine suggest pregnant women are more likely to get severely ill from COVID-19 than women who are not pregnant.
Updates on COVID-19 AstraZeneca and Johnson & Johnson vaccines, and risk of blood clot formation
Vaccination is the main means to control the COVID-19 pandemic worldwide. With such a massive vaccine rollout underway, monitoring the safety of these vaccines is critical and includes the routine reporting and study of rare adverse events.
Vaccines or boosters tailored to the variant first identified in South Africa may be needed
A multi-centered French group, led by Dr. Olivier Schwartz at the Pasteur Institute of Paris, examined how antibodies from previously infected and vaccinated individuals responded to two of the SARS-CoV-2 variants of concern, those first identified in the United Kingdom (B.1.1.7) and South Africa (B.1.351).
Can we stretch our COVID-19 vaccine supply to meet our public health objectives?
The COVID-19 pandemic has created an urgent need to manufacture and distribute vaccines rapidly and widely across the world. Currently, three products (two based on the mRNA platform from Pfizer- BioNTech, Moderna and one based on the adenoviral vector platform from AstraZeneca-Oxford) are being used under emergency-use authorization in vaccination programs around the globe.
Heading in the right direction: a comparison of COVID-19 scenarios
Researchers in Brazil repeatedly measured antibodies against SARS-CoV-2 in blood donors, and found that in the Amazon, close to half of donors were positive for antibodies.